Related references
Note: Only part of the references are listed.Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure
Rossana Roncato et al.
BIOMEDICINE & PHARMACOTHERAPY (2023)
ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites
Alejandra Martinez-Chavez et al.
PHARMACOLOGICAL RESEARCH (2022)
Real world incidence and management of adverse events in patients with HR+, HER2-metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting
Gregory L. Price et al.
CURRENT MEDICAL RESEARCH AND OPINION (2022)
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib
Akimitsu Maeda et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
Rossana Roncato et al.
FRONTIERS IN PHARMACOLOGY (2022)
Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia
Anna Marta Madejczyk et al.
FRONTIERS IN ONCOLOGY (2022)
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal et al.
DRUGS (2021)
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer
Ariana Soledad Poetto et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)
Dose modifications of ribociclib and endocrine therapy for treatment of ER+HER2-metastatic breast cancer
Kristoffer B. Kristensen et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
Hiroji Iwata et al.
ONCOLOGIST (2021)
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
Federica Loscocco et al.
FRONTIERS IN ONCOLOGY (2021)
Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
Natansh D. Modi et al.
BREAST (2021)
Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).
Lorenza Palmero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
Bianca Posocco et al.
PLOS ONE (2020)
Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations
Florent Ferrer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
Rossana Roncato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2-Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial
Veronique Dieras et al.
ONCOLOGIST (2019)
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
Alejandra Martinez-Chavez et al.
MOLECULAR PHARMACEUTICS (2019)
Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro
Ales Sorf et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach
Wan Sun et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Sunil Verma et al.
ONCOLOGIST (2016)
P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib
Mark C. de Gooijer et al.
INVESTIGATIONAL NEW DRUGS (2015)
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub et al.
DRUG METABOLISM AND DISPOSITION (2015)
ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib
Douglas Vivona et al.
ONCOLOGY LETTERS (2014)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients
Suman Lal et al.
CANCER SCIENCE (2008)
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
Jing Li et al.
CANCER BIOLOGY & THERAPY (2007)
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
Erin R. Gardner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)